Trypanosoma cruzi paraflagellar rod proteins 2 and 3 contain immunodominant CD8+ T-cell epitopes that are recognized by cytotoxic T cells from Chagas disease patients

Molecular Immunology

Volumn 52, Issue 3-4, 2012, Pages 289-298

  Egui, Adriana ^a   Thomas, M Carmen ^a   Morell, María ^a   Marañón, Concepción ^a   Carrilero, Bartolomé ^b   Segovia, Manuel ^b   Puerta, Concepción J ^c   Pinazo, María Jesús ^d   Rosas, Fernando ^e   Gascón, Joaquim ^d   López, Manuel Carlos ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^d HOSPITAL CLÍNIC   (Spain)

^e Fundacion Clinica Abood Shaio   (Colombia)

Author keywords

CD8+ T epitope; Chagas disease; Cytotoxic T lymphocytes; Paraflagellar rod proteins (PFRs); Trypanosoma cruzi

Indexed keywords

EPITOPE; GAMMA INTERFERON; GRANZYME B; HEAT SHOCK PROTEIN 70; HLA A ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; PARAFLAGELLAR ROD PROTEIN 2; PARAFLAGELLAR ROD PROTEIN 3; PROTOZOAL PROTEIN; TRYPANOSOMA CRUZI VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EPIMASTIGOTE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; LYSIS; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TRYPOMASTIGOTE;

ANIMALS; ANTIGENS, PROTOZOAN; CELL LINE; CHAGAS DISEASE; EPITOPES, T-LYMPHOCYTE; FEMALE; GRANZYMES; HLA-A2 ANTIGEN; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNODOMINANT EPITOPES; INTERFERON-GAMMA; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRYPANOSOMA CRUZI; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS MUSCULUS; PROTOZOA; TRYPANOSOMA CRUZI;

EID: 84863003591     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.05.021     Document Type: Article

References (40)

1. + T lymphocytes in IFN-gamma ELISPOT assays. Journal of Immunological Methods 2002, 259:95-110.
2. Cazorla S.I., Frank F.M., Malchiodi E.L. Vaccination approaches against Trypanosoma cruzi infection. Expert Review of Vaccines 2009, 8:921-935.
3. Coura J.R., Dias J.C. Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Memorias do Instituto Oswaldo Cruz 2009, 104(Suppl. 1):31-40.
4. Díez H., López M.C., Thomas M.C., Guzman F., Rosa F., Veñazco V., González J.M., Puerta C. Evaluation of IFN-γ production by CD8+ T lymphocytes in response to the K1 peptide from KMP-11 protein in patients infected with Trypanosoma cruzi. Parasite Immunology 2006, 28(3):101-105.
5. Dutra W.O., Rocha M.O., Teixeira M.M. The clinical immunology of human Chagas disease. Trends in Parasitology 2005, 21:581-587.
6. Fonseca C.T., Cunha-Neto E., Kalil J., Jesus A.R., Correa-Oliveira R., Carvalho E.M., Oliveira S.C. Identification of immunodominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells. Memorias do Instituto Oswaldo Cruz 2004, 99:63-66.
7. + epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients. Microbes and infection 2005, 7:688-697.
8. Fouts D.L., Stryker G.A., Gorski K.S., Miller M.J., Nguyen T.V., Wrightsman R.A., Manning J.E. Evidence for four distinct major protein components in the paraflagellar rod of Trypanosoma cruzi. Journal of Biological Chemistry 1998, 273:21846-21855.
9. Garg N., Nunes M.P., Tarleton R.L. Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway. Journal of Immunology 1997, 158:3293-3302.
10. Gowthaman U., Chodisetti S.B., Parihar P., Agrewala J.N. Evaluation of different generic in silico methods for predicting HLA class I binding peptide vaccine candidates using a reverse approach. Amino Acids 2010, 39:1333-1342.
11. Houghten R.A. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proceedings of the National Academy of Sciences of the United States of America 1985, 82:5131-5135.
12. Krausa P., Brywka M., Savage D., Hui K.M., Bunce M., Ngai J.L., Teo D.L., Ong Y.W., Barouch D., Allsop C.E., et al. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 1995, 45:223-231.
13. Kuschnir E., Sgammini H., Castro R., Evequoz C., Ledesma R., Brunetto J. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy. Arquivos Brasileiros de Cardiologia 1985, 45:249-256.
14. + T cells for a promiscuous epitope derived from Trypanosoma cruzi KMP-11 protein in chagasic patients. Parasite Immunology 2010, 32:494-502.
15. Laucella S.A., Postan M., Martin D., Hubby Fralish B., Albareda M.C., Alvarez M.G., Lococo B., Barbieri G., Viotti R.J., Tarleton R.L. The frequency of IFN-γ T cells especific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. Journal of Infectious Diseases 2004, 189:909-918.
16. Luhrs K.A., Fouts D.L., Manning J.E. Immunization with recombinant paraflagellar rod protein induces protective immunity against Trypanosoma cruzi infection. Vaccine 2003, 21:3058-3069.
17. Maga J.A., LeBowitz J.H. Unravelling the kinetoplastid paraflagellar rod. Trends in Cell Biology 1999, 9(10):409-413.
18. Maranon C., Egui A., Carrilero B., Thomas M.C., Pinazo M.J., Gascon J., Segovia M., Lopez M.C. Identification of HLA-A *02:01-restricted CTL epitopes in Trypanosoma cruzi heat shock protein-70 recognized by Chagas disease patients. Microbes and Infection 2011, 12:1525-1532.
19. Maranon C., Planelles L., Alonso C., Lopez M.C. HSP70 from Trypanosoma cruzi is endowed with specific cell proliferation potential leading to apoptosis. International Immunology 2000, 12:1685-1693.
20. Maranon C., Thomas M.C., Planelles L., Lopez M.C. The immunization of A2/K(b) transgenic mice with the KMP11-HSP70 fusion protein induces CTL response against human cells expressing the T. cruzi KMP11 antigen: identification of A2-restricted epitopes. Molecular Immunology 2001, 38:279-287.
21. Marin-Neto J.A., Rassi A., Avezum A., Mattos A.C., Rassi A., Morillo C.A., Sosa-Estani S., Yusuf S. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Memorias do Instituto Oswaldo Cruz 2009, 104(Suppl. 1):319-324.
22. Matsuda N.M., Miller S.M., Evora P.R. The chronic gastrointestinal manifestations of Chagas disease. Clinics (Sao Paulo) 2009, 64(12):1219-1224.
23. + T cell immunity-an infection model for developing T cell vaccine. Parasitology International 2008, 57:38-48.
24. Morell M., Thomas M.C., Caballero T., Alonso C., Lopez M.C. The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosoma cruzi infection. Vaccine 2006, 24:7046-7055.
25. + T cells in Trypanosoma cruzi infection. Current Opinion in Immunology 2009, 21:385-390.
26. Pogue R.R., Eron J., Frelinger J.A., Matsui M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:8166-8170.
27. Portman N., Gull K. The paraflagellar rod of kinetoplastid parasites: from structure to components and function. International Journal for Parasitology 2010, 40:135-148.
28. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infectious Diseases 2001, 1:92-100.
29. Punukollu G., Gowda R.M., Khan I.A., Navarro V.S., Vasavada B.C. Clinical aspects of the Chagas' heart disease. International Journal of Cardiology 2007, 115:279-283.
30. Rassi A., Rassi A. Predicting prognosis in patients with Chagas disease: why are the results of various studies so different?. International Journal of Cardiology 2010, 145:64-65. author reply, pp. 66-67.
31. Sette A., Sidney J., del Guercio M.F., Southwood S., Ruppert J., Dahlberg C., Grey H.M., Kubo R.T. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Molecular Immunology 1994, 31:813-822.
32. Tanowitz H.B., Machado F.S., Jelicks L.A., Shirani J., de Carvalho A.C., Spray D.C., Factor S.M., Kirchhoff L.V., Weiss L.M. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Progress in Cardiovascular Diseases 2009, 51:524-539.
33. Thomas M.C., Garcia-Perez J.L., Alonso C., Lopez M.C. Molecular characterization of KMP11 from Trypanosoma cruzi: a cytoskeleton-associated protein regulated at the translational level. DNA and Cell Biology 2000, 19:47-57.
34. Thomas M.C., Longobardo M.V., Carmelo E., Maranon C., Planelles L., Patarroyo M.E., Alonso C., Lopez M.C. Mapping of the antigenic determinants of the T. cruzi kinetoplastid membrane protein-11. Identification of a linear epitope specifically recognized by human Chagasic sera. Clinical and Experimental Immunology 2001, 123:465-471.
35. + T cell responses. Journal of Immunology 2011, 187:3488-3492.
36. Vazquez-Chagoyan J.C., Gupta S., Garg N.J. Vaccine development against Trypanosoma cruzi and Chagas disease. Advances in Parasitology 2011, 75:121-146.
37. Vitiello A., Marchesini D., Furze J., Sherman L.A., Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. Journal of Experimental Medicine 1991, 173:1007-1015.
38. + TC1 responses. Journal of Immunology 1997, 159:6120-6130.
39. + cytotoxic T lymphocytes target Trypanosoma cruzi-infected host cells. Parasite Immunology 2002, 24:401-412.
40. Wrightsman R.A., Miller M.J., Saborio J.L., Manning J.E. Pure paraflagellar rod protein protects mice against Trypanosoma cruzi infection. Infection and Immunity 1995, 63:122-125.